Press release
Nontuberculous Mycobacterial (NTM) Infections Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Nontuberculous Mycobacterial (NTM) Infections Clinical Trials
As per DelveInsight's assessment, globally, Nontuberculous Mycobacterial (NTM) Infections pipeline constitutes 10+ key companies continuously working towards developing 10+ Nontuberculous Mycobacterial (NTM) Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Nontuberculous Mycobacterial (NTM) Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report here @ Nontuberculous Mycobacterial (NTM) Infections Pipeline Outlook- https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some of the key takeaways from the Nontuberculous Mycobacterial (NTM) Infections Pipeline Report:
• Nontuberculous Mycobacterial (NTM) Infections Companies across the globe are diligently working toward developing novel Nontuberculous Mycobacterial (NTM) Infections treatment therapies with a considerable amount of success over the years.
• Nontuberculous Mycobacterial (NTM) Infections companies working in the treatment market are Mannkind Corporation, Paratek Pharmaceuticals, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others, are developing therapies for the Nontuberculous Mycobacterial (NTM) Infections treatment
• Emerging Nontuberculous Mycobacterial (NTM) Infections therapies such as MNKD-101, Omadacycline, CRS0393, MAT2501, and others are expected to have a significant impact on the Nontuberculous Mycobacterial (NTM) Infections market in the coming years.
• In July 2025, BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multidrug-resistant (MDR) bacteria, announced today a research and exclusive license option agreement with the Japanese pharmaceutical company, Shionogi & Co., Ltd., to jointly develop novel ansamycin leads from BioVersys' BV500 program into clinical candidates. BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate
• In May 2025, Paratek Pharmaceuticals will present clinical findings on NUZYRA Registered (omadacycline) at the American Thoracic Society (ATS) 2025 International Conference. The data comes from a Phase 2, double-blind, randomized, placebo-controlled, multi-center trial assessing the efficacy, safety, and tolerability of oral omadacycline in adult patients with Nontuberculous Mycobacterial Pulmonary Disease (NTM PD) caused by Mycobacterium abscessus complex (MABc).
• In November 2024, Boston-based Paratek Pharmaceuticals announced positive topline results from a Phase IIb trial assessing its oral antibiotic Nuzyra (omadacycline) in adult patients with nontuberculous mycobacterial (NTM) pulmonary disease. The treatment demonstrated at least a 50% improvement in baseline NTM symptoms without any worsening of existing symptoms. While the study was not designed for formal statistical comparisons between treatment groups, the company highlighted that a consistent trend favoring omadacycline was observed across primary and secondary topline endpoints.
• In October 2024, Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant (MDR) bacterial infections, announced the results of a planned interim analysis from its Phase 2a proof-of-concept study of SPR720 for treating NTM-PD. The analysis revealed that the study did not achieve its primary endpoint. Although SPR720 demonstrated antimicrobial activity, it did not show a significant difference from placebo. Additionally, safety concerns emerged at the 1,000 mg once-daily oral dose, including three cases of reversible grade 3 hepatotoxicity. Considering both efficacy and safety data, the company has decided to suspend the SPR720 development program while assessing alternative strategies.
• In April 2024, MannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease.
• In January 2024, Microbion Corporation announced that the company had been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.
• In September 2023, Insmed had reported positive results from the Phase III ARISE study of ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung disease, caused by Mycobacterium avium complex (MAC).
Nontuberculous Mycobacterial (NTM) Infections Overview
Nontuberculous Mycobacterial (NTM) infections are caused by a diverse group of mycobacteria that are commonly found in soil, water, and dust. Unlike Mycobacterium tuberculosis, NTM infections are not contagious and typically affect individuals with compromised immune systems or pre-existing lung conditions, such as chronic obstructive pulmonary disease (COPD) or cystic fibrosis. NTM infections can manifest in various forms, including pulmonary disease, lymphadenitis, skin and soft tissue infections, and disseminated disease.
The most prevalent species responsible for NTM pulmonary infections are Mycobacterium avium complex (MAC) and Mycobacterium abscessus. Symptoms of pulmonary NTM infections often resemble those of other respiratory conditions and may include chronic cough, fatigue, weight loss, and night sweats. Diagnosis typically involves a combination of clinical assessment, imaging studies, and microbiological tests, including culture and molecular techniques.
Treatment of NTM infections is challenging due to the intrinsic resistance of mycobacteria to many antibiotics. A typical treatment regimen includes a combination of multiple antibiotics over an extended period, often 12 months or more, based on the specific NTM species and the patient's response to therapy. Due to the prolonged and complex nature of treatment, patient management often requires a multidisciplinary approach involving pulmonologists, infectious disease specialists, and other healthcare professionals. Despite advances in diagnosis and treatment, NTM infections remain a significant clinical challenge, underscoring the need for ongoing research and development of more effective therapeutic strategies.
Get a Free Sample PDF Report to know more about Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutic Assessment- Nontuberculous Mycobacterial (NTM) Infections Treatment Market - https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Nontuberculous Mycobacterial (NTM) Infections Route of Administration
Nontuberculous Mycobacterial (NTM) Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Nontuberculous Mycobacterial (NTM) Infections Molecule Type
Nontuberculous Mycobacterial (NTM) Infections Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutics Assessment
• Nontuberculous Mycobacterial (NTM) Infections Assessment by Product Type
• Nontuberculous Mycobacterial (NTM) Infections By Stage and Product Type
• Nontuberculous Mycobacterial (NTM) Infections Assessment by Route of Administration
• Nontuberculous Mycobacterial (NTM) Infections By Stage and Route of Administration
• Nontuberculous Mycobacterial (NTM) Infections Assessment by Molecule Type
• Nontuberculous Mycobacterial (NTM) Infections by Stage and Molecule Type
DelveInsight's Nontuberculous Mycobacterial (NTM) Infections Report covers around 10+ products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Nontuberculous Mycobacterial (NTM) Infections product details are provided in the report. Download the Nontuberculous Mycobacterial (NTM) Infections pipeline report to learn more about the emerging Nontuberculous Mycobacterial (NTM) Infections therapies- Nontuberculous Mycobacterial (NTM) Infections Drugs - https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis:
The Nontuberculous Mycobacterial (NTM) Infections pipeline report provides insights into
• The Nontuberculous Mycobacterial (NTM) Infections pipeline report provides detailed insights about companies that are developing therapies for the treatment of Nontuberculous Mycobacterial (NTM) Infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nontuberculous Mycobacterial (NTM) Infections Treatment.
• Nontuberculous Mycobacterial (NTM) Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Nontuberculous Mycobacterial (NTM) Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nontuberculous Mycobacterial (NTM) Infections market.
Download Sample PDF Report to know more about Nontuberculous Mycobacterial (NTM) Infections drugs and therapies- Nontuberculous Mycobacterial (NTM) Infections Clinical Trials and FDA Approvals - https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of Nontuberculous Mycobacterial (NTM) Infections Pipeline Drug Insight
• Coverage: Global
• Key Nontuberculous Mycobacterial (NTM) Infections Companies: Mannkind Corporation, Paratek Pharmaceuticals, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others.
• Key Nontuberculous Mycobacterial (NTM) Infections Therapies: MNKD-101, Omadacycline, CRS0393, MAT2501, and others.
• Nontuberculous Mycobacterial (NTM) Infections Therapeutic Assessment: Nontuberculous Mycobacterial (NTM) Infections current marketed and Nontuberculous Mycobacterial (NTM) Infections emerging therapies
• Nontuberculous Mycobacterial (NTM) Infections Market Dynamics: Nontuberculous Mycobacterial (NTM) Infections market drivers and Nontuberculous Mycobacterial (NTM) Infections market barriers
Request for Sample PDF Report for Nontuberculous Mycobacterial (NTM) Infections Pipeline Assessment and clinical trials - Nontuberculous Mycobacterial (NTM) Infections Therapeutics Market - https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Nontuberculous Mycobacterial (NTM) Infections Report Introduction
2. Nontuberculous Mycobacterial (NTM) Infections Executive Summary
3. Nontuberculous Mycobacterial (NTM) Infections Overview
4. Nontuberculous Mycobacterial (NTM) Infections- Analytical Perspective In-depth Commercial Assessment
5. Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutics
6. Nontuberculous Mycobacterial (NTM) Infections Late Stage Products (Phase II/III)
7. Nontuberculous Mycobacterial (NTM) Infections Mid Stage Products (Phase II)
8. Nontuberculous Mycobacterial (NTM) Infections Early Stage Products (Phase I)
9. Nontuberculous Mycobacterial (NTM) Infections Preclinical Stage Products
10. Nontuberculous Mycobacterial (NTM) Infections Therapeutics Assessment
11. Nontuberculous Mycobacterial (NTM) Infections Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Nontuberculous Mycobacterial (NTM) Infections Companies
14. Nontuberculous Mycobacterial (NTM) Infections Key Products
15. Nontuberculous Mycobacterial (NTM) Infections Unmet Needs
16 . Nontuberculous Mycobacterial (NTM) Infections Market Drivers and Barriers
17. Nontuberculous Mycobacterial (NTM) Infections Future Perspectives and Conclusion
18. Nontuberculous Mycobacterial (NTM) Infections Analyst Views
19. Appendix
20. About DelveInsight
Trending Reports:
• Advanced Recurrent Ovarian Cancer Market: https://www.delveinsight.com/report-store/advanced-recurrent-ovarian-cancer-market
• Aids Related Kaposi's Sarcoma Market: https://www.delveinsight.com/report-store/aids-related-kaposis-sarcoma-market
• Alkaptonuria Market: https://www.delveinsight.com/report-store/alkaptonuria-market
• Anti-gbm Market: https://www.delveinsight.com/report-store/anti-glomerular-basement-membrane-anti-gbm-disease-market-insights
• Cancer Anorexia Market: https://www.delveinsight.com/blog/cancer-anorexia-market
• Chronic Rhinosinusitis Phenotype With Nasal Polyps Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-phenotype-with-nasal-polyps-market-insight
• Duchenne Muscular Dystrophy Market: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market
• Hyperopia Market: https://www.delveinsight.com/report-store/hyperopia-market
• Nonmuscle Invasive Bladder Cancer Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• Oral Mucositis Om Market: https://www.delveinsight.com/report-store/oral-mucositis-om-market
• Severe Hypertriglyceridemia Market: https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Bk Virus Infection Market: https://www.delveinsight.com/report-store/bk-virus-bkv-infection-market
• Human Papillomavirus Positive Cancer Market: https://www.delveinsight.com/report-store/human-papillomavirus-16-positive-hpv16-cancers-market
• Intrahepatic Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anti-cd274 Pd-l1 Antibody Pipeline: https://www.delveinsight.com/report-store/anti-cd274-pd-l1-antibody-pipeline-insight
• Antibody-mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Bone And Joint Infection Market: https://www.delveinsight.com/report-store/prosthetic-joint-infection-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Cardiorenal Syndrome Market: https://www.delveinsight.com/report-store/cardiorenal-syndrome-market
• Facioscapulohumeral Muscular Dystrophy Market: https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-market
• Menorrhalgia Market: https://www.delveinsight.com/report-store/menorrhalgia-market
• Postmenopausal Vaginal Atrophy Market: https://www.delveinsight.com/infographics/atrophic-vaginitis-market
• Uncomplicated Urinary Tract Infections Market: https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
• Balloon Catheters Market: https://www.delveinsight.com/report-store/balloon-catheters-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Cutaneous Lupus Erythematosus Market: https://www.delveinsight.com/report-store/cutaneous-lupus-erythematosus-market
• Vascular Dementia Market: https://www.delveinsight.com/report-store/vascular-dementia-market
• West Syndrome Market: https://www.delveinsight.com/report-store/west-syndrome-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/asco-conference-coverage
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nontuberculous Mycobacterial (NTM) Infections Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 4137629 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for NTM
Nontuberculous Mycobacterial Infection Market Outlook 2034 - Clinical Trials, Ma …
Nontuberculous Mycobacterial Infections Market Size in the US was approximately USD 360 million in 2023 and is projected to increase during the forecast period (2024-2034).
Nontuberculous Mycobacterial Market Summary
The Nontuberculous Mycobacterial (NTM) infections market is expected to grow steadily from 2024 to 2034, driven by improved diagnostics, new therapies, and greater disease awareness. Aging populations, who are more susceptible to NTM infections, contribute to rising diagnosed cases. Current treatments rely on…
Nontuberculous Mycobacterial Infections Treatment Market Size in the US was ~USD …
DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.
Discover Key Insights into the Nontuberculous Mycobacterial Market with DelveInsight's In-Depth Report @ Nontuberculous Mycobacterial Market Size [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Nontuberculous Mycobacterial Market Report
* In December 2024:- Parateek Pharmaceuticals- The purpose of this…
Nontuberculous Mycobacterium Treatment Market Forecasted to Achieve a CAGR of 7. …
Nontuberculous Mycobacterium Treatment Market Overview
The Nontuberculous Mycobacterium (NTM) Treatment Market was valued at USD 5.32 Bn in 2024. It is expected to reach USD 9.5 Bn by 2032, with a CAGR of 7.52% during the forecast period from 2025 to 2032.
The Nontuberculous Mycobacterium (NTM) Treatment Market is centered around the management and therapeutic options available for infections caused by nontuberculous mycobacteria, which are environmental organisms distinct from the mycobacteria responsible…
Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis 2024: FDA Approv …
NTM Infection companies are Mannkind Corporation, Paratek Pharmaceuticals, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others.
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Nontuberculous Mycobacterial (NTM) Infections pipeline constitutes 10+ key companies continuously working towards developing 10+ Nontuberculous Mycobacterial (NTM) Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Nontuberculous Mycobacterial (NTM) Infections Pipeline Insight, 2024" report by…
Hydrogen Concentration Sensors for Vehicle Market is Thriving Worldwide with Top …
Hydrogen Concentration Sensors for Vehicle Market Overview: Owing to a boom in the commercial industry, the demand for hydrogen sensors in automobiles is rising. Many certifying authorities employ sensors to assess the level of pollutants or the leaking in the cars. The need will increase as a result of technological developments and study expenditures for the creation of novel and inventive vehicle hydrogen sensor goods. The civilized world has a…
Global Waste or Garbage Collection Vehicle Market 2022 Development Factors - AUT …
The Global Waste or Garbage Collection Vehicle Market by MarketandResearch.biz assesses current market circumstances and forecasts industry growth for 2022-2028. This research examines current growth patterns, current growth factors, and future development projections in depth.
There are multiple sections to this. The market potential of each geographic location is assessed in terms of growth rate, macroeconomic indicators, and consumer purchasing habits in this study. Firms and other clients can utilise the…
